Pushing the treatment envelope for chronic hepatitis C - Is more necessarily better?

Hepatology

Volumn 41, Issue 2, 2005, Pages 234-236

  Ghany, Marc ^a   Lutchman, Glen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOVIRIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAMIDINE; RIBAVIRIN; RNA POLYMERASE; VIRUS RNA;

ANTIVIRAL ACTIVITY; BLOOD TRANSFUSION; BODY WEIGHT; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GENOTYPE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; LOW DRUG DOSE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 12844272774     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20605     Document Type: Editorial

References (14)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. Food and Drug Administration Center for Drug Evaluation and Research Meeting of the Antiviral Drugs Advisory Committee. www.fda.gov/ohrms/dockets/ac/ 01/briefing/3819b1_03_FDA-Clinical%20review.htm 2003.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
5. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004;40:1260-1265.
6. Lindahl K SL, Bruchfeld A, Schvarcz R. High dose ribavirin in combination with standard dose peginterferon for treatment of chronic hepatitis C patients. HEPATOLOGY 2005;41:275-279.
7. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-2271.
8. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-1323.
9. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared wich interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenrerol 2004;99:1490-1496.
10. Gish RG, Arora S,, Nelson D, Fried MW, Reddy KR, Xu Y, et al. End-of-treatment (EOT) response in therapy-naïve patients treated for hepatitis C with viriamidine in combination with pegylated interferon alfa-2a [Abstract]. HEPATOLOGY 2004;40:388A.
11. Pockros PJ, Pessoa MG, Diago M, de Lôurdes Candolo Martinelli A, Berg T, Germanidis, et al. Combination of levovorin (LVV) and peginterferon alfa-2a (40Kd) Pegasys®) fails to generate a virological response comparable to ribavrin (RBV, Copegus®) and peginterferon alfa-2a (40Kd) in patients with chronic hepatitis C [Abstract]. HEPATOLOGY 2004;40:391A.
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
13. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
14. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, et al. Longer treatment duration with peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin (Copegus®) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: Final results of the randomized, multicenter TERAVIC-4 study [Abstract]. HEPATOLOGY 2004;40:218A.